Equillium, Inc.

NASDAQ:EQ

Biotechnology

Healthcare
$1.10 +1.51%

+$0.05 today

Market cap
$90.56M
Beta
1.76
P/E (TTM)
-15.3
EPS (TTM)
-$0.20
52W Low $0.27High $3.45

Volume 0.89M

Average 0.60M

EQ Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Equillium, Inc.NASDAQ: EQ

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $434K rose 13.9% year over year, ahead of the -646.1% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +13.9% holds above the trailing-twelve-month pace of -646.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$434K+1415.2% QoQ
Last fiscal yearDec 2025
-$1.94M-2.9% YoY
LTMMar 2026
-$1.88M-646.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.9%——
1 year-2.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.94M) USD
Year-over-year change
+2.9%

Accounts Payables vs competitors

How EQ compares with its peers on the latest reported figures

  • EQ's LTM Mar 2026 accounts payables of $1.88M is the 4th largest of the 10 companies compared; the peer median is $64K.
  • Its year-over-year change of -646.1% is the lowest of 10, against a peer median of +100.9%.
EQ Competitors Peer median
Accounts Payables for EQ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$37.42M +505.9%—56.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$12.2M +1170.0%+236.9%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$4.9M +28.5%+8.8%1472.1%
EQEquillium, Inc.LTM Mar 2026$1.88M -646.1%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026$764K +6466.7%-36.8%—
CUECue Biopharma, Inc.LTM Mar 2026$458K +239.3%+138.4%1.4%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$424K -76.4%——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$109.49K -55.4%+121.5%7.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$64K +100.9%—2.8%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$49.76K -145.7%——
Peer median (excluding EQ) $64K+100.9%+121.5%7.7%

Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.05M)(62.43M)(13.34M)(8.07M)(22.4M)
Depreciation & Amortization72K118K126K137K116K
Deferred Income Tax554K0000
Stock-Based Compensation4.41M4.84M4M3.75M2.32M
Change in Working Capital1.7M19K(2.55M)842K(2.32M)
Accounts Receivables0(2.84M)(897K)3.74M0
Inventory00000
Accounts Payables(1.58M)2.51M723K(2M)(1.94M)
Other Working Capital3.28M349K(2.37M)(898K)(380K)
Other Non-Cash Items237K48.72M(10.03M)(15.69M)(469K)
Operating Cash Flow(32.08M)(8.73M)(21.78M)(19.03M)(22.75M)
Capital Expenditures(57K)(279K)(50K)(85K)(48K)
Acquisitions (Net)0700K0012K
Purchases of Investments(32.99M)(14.96M)(54.71M)(17.6M)0
Sales of Investments60.46M33.23M50M31.5M4.5M
Other Investing Activities00000
Investing Cash Flow27.41M18.68M(4.76M)13.81M4.46M
Debt Repayment0(1.43M)(9.13M)00
Common Stock Issued29.91M214K0164K30.43M
Common Stock Repurchased00(260K)00
Dividends Paid00000
Other Financing Activities1.15M0165K00
Financing Cash Flow31.06M(1.22M)(9.23M)164K30.43M
Effect of Forex Changes(2K)5K(118K)(83K)47K
Net Change in Cash26.38M8.74M(35.89M)(5.13M)12.19M
Free Cash Flow(32.14M)(9.01M)(21.83M)(19.11M)(22.79M)

Equillium, Inc.

NASDAQ:EQ

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.